OPKO Health, Inc.

OPKO Health, Inc. is a diversified, publicly traded healthcare company founded in 1991 and based in Miami, Florida. Operating in over 30 countries, OPKO combines three core business segments: diagnostics, pharmaceuticals, and specialty therapeutics. BioReference Laboratories, one of the largest full-service clinical reference laboratories in the United States, serves approximately 11 million patients annually and offers comprehensive genetic testing, specialized diagnostics, and innovative testing platforms including the 4Kscore Test for prostate cancer detection. The pharmaceutical division focuses on research and development of next-generation therapies, particularly multispecific antibodies targeting cancers and infectious diseases. OPKO's marketed therapies include NGENLA™, an FDA-approved human growth hormone for pediatric growth hormone deficiency (partnered with Pfizer and approved in over 40 markets), and RAYALDEE® for secondary hyperparathyroidism treatment. The company maintains strategic partnerships with leading global organizations including Pfizer, Merck, NIH, BARDA, and Duke University, supporting its commitment to advancing innovative therapeutic solutions for serious medical conditions.